Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duopresinn is a fixed-dose combination of olmesartan medoxomil and amlodipine besylate used for the treatment of hypertension. Olmesartan is an angiotensin II receptor antagonist (ARB) that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 receptor in vascular smooth muscle and the adrenal gland. Amlodipine is a dihydropyridine calcium channel blocker (CCB) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in peripheral arterial vasodilation and reduced peripheral vascular resistance. The combination of these two antihypertensive agents provides a synergistic effect in lowering blood pressure, often used when monotherapy is insufficient. It is distributed by INNventa Pharm as a branded generic product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on olmesartan + amlodipine.